NightHawk Biosciences Inc (NHWK): The presentation is well worth listening...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5698
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: Bonou2 post# 1045

Wednesday, 09/21/2016 6:32:19 PM

Wednesday, September 21, 2016 6:32:19 PM

The presentation is well worth listening to! The slides are not new...however Wolf's words must be listened to very carefully. He said that there are four data readouts coming in Q4.

1. Bladder cancer: phase 2 HS-410 combined with BCG
2. Bladder cancer: phase 2 HS-410 monotherapy
3. Lung cancer: phase 2 HS-110 + low dose cyclophosphomide
4. Lung cancer: phase 1b HS-110 + nivolimab

Wolf began by saying they "are focussed on progressing our two lead programs through the clinic". This could mean two phase 3 trials very soon. I expect they would follow the very common practice of small biotechs and partner for the phase 3 trials. At the end of his presentation Wolf was asked a question about the relationship with BMS and said that there was no formal relationship with BMS " at this point".

Wolf also said that they intend to institute a second-generation ComPACT clinical trial "as soon as possible". In my opinion I would expect any potential partner to be very interested in partnering for such a trial!

"The refusal of the real is the number one dogma of our time" Rene Girard